| Menghini-type | Conventional-type | P value |
---|---|---|---|
(N = 14) | (N = 14) | ||
Male (n [%]) | 11 (71) | 12 (86) | 0.622 |
Age (years, median [range]) | 71 (50–79) | 62 (54–75) | 0.018 |
Obstructive jaundice (n [%]) | 4 (29) | 4 (29) | 1.000 |
HbA1c (%, median [range]) | 7.3 (5.2–11.7) | 5.8 (5.1–8.7) | 0.032 |
Diagnosis using the ICDC without histological findings of EUS-guided approach (n [%]) | |||
 Definitive type 1 AIP | 13 (93) | 10 (71) | 0.139 |
 Not definitive type 1 AIP | 1 (7) | 4 (29) |  |
 Type 2 AIP | 0 | 0 |  |
Median follow-up period (days [range]) | 1116 (297–3303) | 1747(683–3303) | 0.028 |
Pancreatic imaging | |||
 Enlargement with delayed enhancement |  |  |  |
 Diffuse/Segmental or Focal | 11/3 | 7/7 | 0.052 |
 MPD narrowing |  |  |  |
 Long (≥ 1/3) or multiple/Segmental or Focal | 11/2 | 6/4 | 0.115 |
 Location of the enlarged part |  |  | 0.412 |
 Whole | 8 (57) | 7 (50) |  |
 Head | 1 (7) | 1 (7) |  |
 Body | 0 | 1 (7) |  |
 Tail | 0 | 2 (14) |  |
 Head and body | 0 | 1 (7) |  |
 Body and tail | 3 (21) | 1 (7) |  |
 Head and tail | 2 (14) | 1 (7) |  |
Serology | |||
 IgG4 (mg/dl, median [range]) | 364.3 (104–1090) | 267 (32–1270) | 0.828 |
 IgG4 ≥ 135 mg/dl (N [%]) | 11 (79) | 11 (79) | 1.000 |
 Level 1, ≥ 270 mg/dl | 9 (64) | 7 (50) |  |
 Level 2, ≥ 135 mg/dl but < 270 mg/dl | 2 (14) | 4 (29) |  |
Other organ involvement | |||
 Sclerosing cholangitis | 5 (36) | 6 (43) | 0.699 |
 Retroperitoneal fibrosis | 4 (29) | 3 (21) | 0.663 |
 IgG4-related kidney disease | 3 (21) | 0 | 0.067 |
 Sialadenitis | 2 (14) | 0 | 0.142 |
 Dacryoadenitis | 1 (7) | 0 | 0.309 |
 Inflammatory bowel disease | 0 | 0 | – |
Response to steroids (n [%]) | 14 (100) | 11a (100) | – |